** Biotechnology firm CSL's CSL.AX shares drop as much as 0.7%
** Morgan Stanley flags a 15% drop in influenza vaccine sales during the first half, pointing to a decline in U.S. vaccination rates for those aged 15 to 64 as key contributor to its sales slump in the country
** Brokerage highlights that U.S. CDC has classified 2024-25 as a high-severity influenza season for all age groups — the first since 2017-18
** Despite the current reduction in sales, Morgan Stanley suggests that severity of current season may support increased vaccination rates for the upcoming season
** Rates stock "overweight" at the price target of A$313/shr
** Stock down 9.9% YTD including current trading session
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk http://www.x.com/thatstanishk))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.